⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GMAB News
Genmab A/S ADS
Genmab Announces Rinatabart Sesutecan (Rina-S ®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
businesswire.com
GMAB
Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
globenewswire.com
GMAB
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
prnewswire.com
EXEL
LLY
RVMD
ONCY
GMAB
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026
globenewswire.com
GMAB
Recurrent Head And Neck Squamous Cell Carcinoma Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 65+ Leading Players Wheeling the Therapeutics Landscape
globenewswire.com
GSK
JNJ
MRK
REGN
BIIB
EXEL
IOBT
INO
GMAB
IMUX
NVCR
PDSB
BNTX
CRSP
MRNA
RPTX
PRE
TRNS
INVZ
Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members
globenewswire.com
GMAB
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
globenewswire.com
GMAB
ABBV
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
prnewswire.com
ABBV
GMAB
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
businesswire.com
ABBV
GMAB
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
globenewswire.com
GMAB
ABBV